Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference.
As with other protein therapeutics, trebananib (AMG 386), an investigational peptide Fc-fusion protein ("peptibody") that inhibits angiogenesis by neutralizing the interaction of angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2) with the Tie2 receptor, has the potential to trigger an immune response in cancer patients treated with the therapeutic. An electrochemiluminescence bridging anti-drug antibody (ADA) assay that was utilized to support early-phase clinical trials in the development of trebananib was found to lack adequate sensitivity and drug tolerance in later-phase clinical studies when higher doses of trebananib were administered. Therefore, we developed a surface plasmon resonance (SPR) immunoassay method utilizing a secondary confirmatory detector antibody (goat anti-human IgG F[ab']2) known to cross-react with human IgG and IgM to better assess the potential impact of immunogenicity on the pharmacokinetics, pharmacodynamics, and toxicity of trebananib. The SPR method was more sensitive than the electrochemiluminescence bridging assay because of signal amplification from the confirmatory binding of the detector antibody; drug tolerance was improved since antibody binding avidity does not affect detection on this platform. Despite the inability of the confirmatory detector antibody to bind angiopoietins in protein-free buffer, false-positive ADA results were generated from patient serum samples containing Ang1 and Ang2 through an apparently specific binding between the angiopoietins and the confirmatory detector antibody, likely mediated by the interaction of the angiopoietins with serum immunoglobulins. Addition to the sample diluent of a human antibody that specifically binds to Ang1 and Ang2 with high affinity resulted in a complete block of angiopoietin interference without affecting ADA detection. This biosensor-based assay provides a reliable method for assessing immunogenicity in phase 3 clinical trials.
Department of Clinical Immunology, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. Electronic address: dohanw@amgen.com.
Dohan K
DK
Weeraratne
James
J
Lofgren
Steve
S
Dinnogen
Steven J
SJ
Swanson
Zhandong Don
ZD
Zhong
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000032:analysis* / Q000494:pharmacology; D042683:Angiopoietin-1 / Q000378:metabolism; D042702:Angiopoietin-2 / Q000378:metabolism; D000888:Antibodies, Anti-Idiotypic / Q000097:blood; D015374:Biosensing Techniques / Q000379:methods*; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007075:Immunoglobulin M / Q000097:blood / Q000276:immunology; D049449:Luminescence; D009389:Neovascularization, Pathologic; D042787:Receptor, TIE-2 / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000032:analysis* / Q000494:pharmacology; D020349:Surface Plasmon Resonance
D020533:Angiogenesis Inhibitors; D042683:Angiopoietin-1; D042702:Angiopoietin-2; D000888:Antibodies, Anti-Idiotypic; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D011993:Recombinant Fusion Proteins; D042787:Receptor, TIE-2; C551398:trebananib
ADA; AMG 386; Ang1; Ang2; Anti-drug antibody; Biacore®; ECL; Ig; Immunogenicity; K(D); MSD; Meso Scale Discovery; RU; S/N; SPR; Soluble drug target interference; Trebananib; affinity constant; angiopoietin-1; angiopoietin-2; anti-drug antibody; association rate constant; dissociation rate constant; electrochemiluminescence; immunoglobulin; k(a); k(d); response unit; signal-to-noise ratio; surface plasmon resonance